Agilent Technologies, Inc. logo
Agilent Technologies, Inc. (A)
Compare

Agilent Technologies, Inc. (A) Short-Term Debt

The short-term debt for Agilent Technologies, Inc. (A) is $304.00 Million with a year-over-year change of +575.56%. Short-term debt includes all borrowings and debt obligations due within one year, including the current portion of long-term debt, commercial paper, and credit facilities.

A Short-Term Debt Chart

A Short-Term Debt
$304.00M
Zoom

Current Short-Term Debt

$304.00M

$304.00 Million

Year-over-Year Change

+575.56%

vs. $45.00M prior year

Historical Data

28

Years of data available

Annual Short-Term Debt History

YearShort-Term DebtYoY Change% Change
2025$304.00M+$259.00M+575.56%
2024$45.00M+$45.00M
2023$0$-36.00M-100.00%
2022$36.00M+$36.00M
2021$0$-75.00M-100.00%
2020$75.00M$-541.00M-87.82%
2019$616.00M+$616.00M
2018$0$-210.00M-100.00%
2017$210.00M+$210.00M
2016$0+$0
2015$0+$0
2014$0+$0
2013$0$-250.00M-100.00%
2012$250.00M$-3.00M-1.19%
2011$253.00M$-1.25B-83.14%
2010$1.50B+$1.50B+150000.00%
2009$1.00M+$1.00M
2008$0+$0
2007$0+$0
2006$0+$0
2005$0+$0
2004$0+$0
2003$0+$0
2002$0$-6.00M-100.00%
2001$6.00M$-104.00M-94.55%
2000$110.00M+$110.00M
1999$0+$0
1998$0
Data as of Thursday, June 11, 2026

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell